Clinical Policy Title:	tezacaftor/ivacaftor
Policy Number:	RxA.487
Drug(s) Applied:	Symdeko®
Original Policy Date:	03/06/2020
Last Review Date:	08/28/2024
Line of Business Policy Applies to:	All lines of business (except Medicare)

# Criteria

#### ١. **Initial Approval Criteria**

- A. Cystic Fibrosis (must meet all):
  - 1. Diagnosis of cystic fibrosis (CF) confirmed by one of the following (a or b):
    - a. Homozygous for F508del mutation in the CFTR gene;
    - b. Presence of at least one mutation in the CFTR gene that is responsive to Symdeko® based on in vitro data or clinical evidence.

### **Approval Duration**

All Lines of Business (except Medicare): 12 months

#### II. **Continued Therapy Approval**

- A. Cystic Fibrosis (must meet all):
  - 1. Member is currently receiving or has been treated with this medication within the past 120 days, excluding manufacturer samples;
  - 2. Member is responding positively to therapy as evidenced by a stabilization in ppFEV1 if baseline was > 70% or increase in ppFEV1 if baseline was < 70%.

## **Approval Duration**

All Lines of Business (except Medicare): 12 months

## References

1. Ren CL, Morgan RL, Oermann C, et al. Cystic Fibrosis Foundation pulmonary guidelines: Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis. Ann Am Thorac Soc. 2018; 15(3): 271-280. Available at: https://pubmed.ncbi.nlm.nih.gov/29342367/. Accessed August 28, 2024.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy was established	01/2020	03/06/2020
<ul> <li>Policy was reviewed:</li> <li>1. Policy title table was updated: Line of business policy applies was updated to all lines of business.</li> <li>2. Continued therapy criteria II.A.1 was rephrased to "Currently receiving medication that has been authorized by RxAdvance".</li> </ul>	10/01/2020	12/07/2020

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

© 2024 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited. Revised 08/2024



3. References were updated.		
<ul> <li>Policy was reviewed:</li> <li>1. Continued Therapy Criteria II.A.1 was rephrased to "Member is currently receiving medication that has been authorized by RxAdvance".</li> <li>2. References were reviewed and updated.</li> </ul>	09/4/2021	12/7/2021
Policy was reviewed: 1. References were reviewed and updated.	04/05/2022	07/18/2022
<ul> <li>Policy was reviewed: <ol> <li>Initial Approval Criteria, I.A.1.a and 1.A.1.b: Updated to remove diagnostic criteria " <ol> <li>Clinical symptoms consistent with CF in at least one organ system, or positive newborn screen or genetic testing for siblings of patients with CF;</li> <li>Evidence of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction confirmed by one of the following (i or ii): <ol> <li>Elevated sweat chloride ≥ 60 mmol/L;</li> <li>Genetic testing confirming the presence of two disease-causing mutations in CFTR gene, one from each parental allele."</li> </ol> </li> <li>Initial Approval Criteria, I.A.4: Update to remove documentation criteria "Chart notes indicate that pulmonary function tests, performed within the last 90 days, show a percent predicted forced expiratory volume in 1 second (ppFEV1) that is between 40- 90%."</li> <li>Initial Approval Criteria, I.A.5: Update to remove prior cuncurrent therapy criteria "Symdeko® is not prescribed concurrently with other CFTR modulators (e.g., Kalydeco®, Orkambi®, Trikafta®)."</li> <li>Initial Approval Criteria, I.A. Updated Approval duration from 6 to 12 months for Commercial and Medicaid.</li> <li>Continued Therapy Approval Criteria II.A.3: Update to remove prior cuncurrent therapy criteria "Symdeko® is not prescribed concurrently with other CFTR modulators (e.g., Kalydeco®, Orkambi®, Trikafta®)."</li> </ol> </li> </ol></li></ul>	04/28/2023	07/13/2023

© 2024 RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited. Revised 08/2024 v 2.0.01.1



6. References were reviewed and updated.		
Policy was reviewed.	10/19/2023	10/19/2023
<ol> <li>Policy was reviewed:         <ol> <li>Removed age restrictions.</li> <li>Removed prescriber restrictions.</li> <li>Removed dose restrictions.</li> <li>Updated Continued therapy approval with the new verbiage containing 120 days lookback period.</li> </ol> </li> </ol>	08/28/2024	09/13/2024
<ol> <li>Removed reauthorization requirement for positive response to therapy.</li> </ol>		
<ol> <li>Updated approval duration verbiage.</li> <li>References were reviewed and updated.</li> </ol>		